|
Orthologous residues
|
|
CDK2 (human): T39‑p, CDK2 (mouse): T39‑p, CDK2 (rat): T39‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), 3T3 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
co-immunoprecipitation, phospho-motif antibody
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
serum starvation
|
|
|
|
decrease
|
|
|
serum
|
serum starvation
|
|
|
inhibit treatment-induced decrease
|
|
|
EGF
|
serum starvation
|
|
|
inhibit treatment-induced decrease
|
|
|
rapamycin, EGF
|
serum starvation
|
|
|
inhibit treatment-induced decrease
|
|
|
EGF, wortmannin
|
serum starvation
|
|
|
no effect upon treatment-induced decrease
|
|
|
EGF, Akt-I-1
|
serum starvation
|
|
|
no effect upon treatment-induced decrease
|
|
|
methotrexate
|
|
|
|
increase
|
|
|
roscovitine
|
methotrexate
|
|
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
methotrexate
|
|
|
inhibit treatment-induced increase
|
|
|
docetaxel
|
|
|
|
increase
|
|
|
roscovitine
|
docetaxel
|
|
|
inhibit treatment-induced increase
|
|
|
wortmannin
|
docetaxel
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Effect of modification (process):
apoptosis, induced, cell cycle regulation
|
|
Comments:
contributes to the cell death induced by methotrexate and docetaxel
|
